H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $30 and keeps a Buy rating on the shares. The firm cites “consistent” key opinion leader support for the lorundrostat ASI approach to hypertension for the target increase. The analyst is “enthusiastic” for lorundrostat “supporting a differentiated and viable path forward” for treating hypertension patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- 3 Best Stocks to Buy Now, 4/1/2025, According to Top Analysts
- Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat
- 3 Best Stocks to Buy Now, 3/31/2025, According to Top Analysts
- Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial
- Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics